Neuroscientific Biopharmaceuticals Ltd. (AU:NSB) has released an update.
NeuroScientific Biopharmaceuticals Ltd is making strides in its glaucoma treatment with the start of IND-enabling studies for EmtinB, following a successful pre-IND meeting with the FDA. The company maintains a strong financial footing with a cash balance of A$4.74 million, carefully managing expenses while exploring new opportunities to enhance its portfolio. These developments could bring the company closer to securing FDA approval for clinical trials, potentially impacting its stock performance.
For further insights into AU:NSB stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
